782PSAFETY OF CABAZITAXEL + PREDNISONE (CBZ + P) IN PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH DOCETAXEL (DOC): COHORT COMPASSIONATE-USE PROGRAMME (CUP).

@article{Heidenreich2014782PSAFETYOC,
  title={782PSAFETY OF CABAZITAXEL + PREDNISONE (CBZ + P) IN PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH DOCETAXEL (DOC): COHORT COMPASSIONATE-USE PROGRAMME (CUP).},
  author={Axel Heidenreich and H. C. Scholz and Hamiyet Ozen and Choosak Pripatnanont and Inge M. van Oort and Winald R. Gerritsen and Constantinos Efstathiou and Joachim Rinck and Jae Chel Lee and A Boumessous and Zhen Tao Su and Simon Hitier and Alexandros S Ardavanis},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2014},
  volume={25 suppl_4},
  pages={iv270}
}
A. Heidenreich1, H. Scholz2, H. Ozen3, C. Pripatnanont4, I.M. van Oort5, W. R. Gerritsen6, E. Efstathiou7, J.A. Rinck Jr.8, J. Lee9, A. Boumessous10, Z. Su11, S. Hitier12, A. Ardavanis13 Department of Urology, Uniklinik RWTH Aachen, Aachen, GERMANY Department of Urology, Asklepios Klinik Weissenfels-Hohenmölsen, Weissenfels, GERMANY Department of Urology, Hacettepe University Medical Faculty, Ankara, TURKEY Department of Surgery, Faculty of Medicine, Prince of Songkla University, Songkla… CONTINUE READING